Scinai Immunotherapeutics Aktie - SCNI

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,28

Gebot

3,24

Fragen

3,34

Volumen

1.680

3,25 Tagesbereich 3,40

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

2,746M

Handelsende

3,28

Handelsbeginn

3,25

Letzte Trade

3.29

Letzter Handelszeitpunkt

15:43:28

Finanzvolumen

US$ 5.561

VWAP

3,3102

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

837.310

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

Nettogewinn

-6,5M

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic ... BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Coml Physical, Biologcl Resh

Website

www.biondvax.com

Hauptsitz

Jerusalem, Jerusalem, Isr

Gegründet

2012

Scinai Immunotherapeutics Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SCNI. The last closing price for Scinai Immunotherapeutics was US$3,28. Over the last year, Scinai Immunotherapeutics shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Scinai Immunotherapeutics currently has 837.310 shares in issue. The market capitalisation of Scinai Immunotherapeutics is US$2,75 million.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT PR Newswire JERUSALEM, March...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences PR Newswire JERUSALEM, Jan...

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. PR...

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

SCNI - Frequently Asked Questions (FAQ)

What is the current Scinai Immunotherapeutics share price?

The current share price of Scinai Immunotherapeutics is US$ 3,28

How many Scinai Immunotherapeutics shares are in issue?

Scinai Immunotherapeutics has 837.310 shares in issue

What is the market cap of Scinai Immunotherapeutics?

The market capitalisation of Scinai Immunotherapeutics is USD 2,75M

What is the 1 year trading range for Scinai Immunotherapeutics share price?

Scinai Immunotherapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Scinai Immunotherapeutics?

Scinai Immunotherapeutics reports financial results in USD

What is the latest annual turnover for Scinai Immunotherapeutics?

The latest annual turnover of Scinai Immunotherapeutics is USD 9k

What is the latest annual profit for Scinai Immunotherapeutics?

The latest annual profit of Scinai Immunotherapeutics is USD -6,5M

What is the registered address of Scinai Immunotherapeutics?

The registered address for Scinai Immunotherapeutics is JERUSALEM BIOPARK, 2ND FLOOR, HADASSAH EIN KEREM CAMPUS, JERUSALEM, JERUSALEM, 7403618

What is the Scinai Immunotherapeutics website address?

The website address for Scinai Immunotherapeutics is www.biondvax.com

Which industry sector does Scinai Immunotherapeutics operate in?

Scinai Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SYRSSyros Pharmaceuticals Inc	US$ 0,2201 (140,28%)	480,61M
TSVT2seventy bio Inc	US$ 4,93 (76,07%)	23,02M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0544 (62,39%)	171,39M
RAYRaytech Holding Ltd	US$ 1,34 (54,02%)	16,54M
CUTRCutera Inc	US$ 0,1849 (43,89%)	172,48M
ARVNArvinas Inc	US$ 8,15 (-53,59%)	7,36M
LZMHLZ Technology Holdings Ltd	US$ 7,56 (-51,72%)	281,27k
SPGCSacks Parente Golf Inc	US$ 0,1038 (-35,17%)	19,41M
BDRXBiodexa Pharmaceuticals PLC	US$ 2,0399 (-28,42%)	464,86k
XAGELongevity Health Holdings Inc	US$ 0,235 (-26,56%)	1,68M
SYRSSyros Pharmaceuticals Inc	US$ 0,2202 (140,39%)	473,8M
CUTRCutera Inc	US$ 0,182 (41,63%)	171,46M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,054701 (63,29%)	171M
AWHAspira Womans Health Inc	US$ 0,2562 (29,39%)	161,16M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7,435 (0,75%)	134,77M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Scinai Immunotherapeutics Ltd (SCNI)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Scinai Immunotherapeutics Ltd

SCNI Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

SCNI - Frequently Asked Questions (FAQ)

Beweger

SCNI Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Scinai Immunotherapeutics Ltd (SCNI) Börsenkurse

Scinai Immunotherapeutics Ltd (SCNI)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Scinai Immunotherapeutics Ltd

SCNI Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

SCNI - Frequently Asked Questions (FAQ)

Beweger

SCNI Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR